CHOLESTASIS and Dopamine


CHOLESTASIS Symptoms and Causes

Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes.

Different diseases can block the bile ducts and cause a problem with the flow of bile:

  • Gallstones, which can increase pressure in the gallbladder and cause a gallbladder attack. The pain usually lasts from one to several hours.
  • Cancer
  • Infections
  • Birth defects, such as biliary atresia. It is the most common reason for liver transplants in children in the United States.
  • Inflammation, which can cause scarring. Over time, this can lead to liver failure.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for CHOLESTASIS

CHOLESTASIS treatment research studies

Dopamine clinical trials, surveys and public health registries

Find Drug Side Effect reports

Dopamine Side Effects

Renal Failure (24)
Injury (23)
Unevaluable Event (21)
Fear (20)
Pain (19)
Renal Injury (18)
Death (17)
Emotional Distress (16)
Renal Impairment (15)
Anxiety (15)
Multi-organ Failure (14)
Stress (14)
Hypotension (11)
Device Failure (11)
Anhedonia (10)
Blood Pressure Decreased (10)
Device Malfunction (9)
Cardiac Arrest (9)
Depression (7)
Cardio-respiratory Arrest (5)
Loss Of Consciousness (5)
Incorrect Dose Administered (5)
Electrocardiogram St Segment Elevation (4)
Hypernatraemia (4)
Cerebrovascular Accident (4)
Bradycardia (4)
Renal Failure Acute (4)
Myocardial Infarction (4)
Ventricular Fibrillation (4)
Ventricular Tachycardia (4)
Pulse Absent (4)
Acidosis (3)
Accidental Overdose (3)
Acute Respiratory Distress Syndrome (3)
Blood Pressure Systolic Decreased (3)
Choreoathetosis (3)
Condition Aggravated (3)
Blood Pressure Immeasurable (3)
Atrial Fibrillation (3)
Confusional State (3)
Encephalitis (3)
Depressed Level Of Consciousness (3)
Tachycardia (3)
Hypertension (3)
Metabolic Acidosis (3)
Rhabdomyolysis (3)
Mitral Valve Incompetence (3)
Nausea (2)
Pancytopenia (2)
Nervousness (2)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

CHOLESTASIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants
Conditions: Cholestasis;   Prematurity;   Gastroschisis;   Intestinal Atresia;   Necrotizing Enterocolitis
Intervention: Drug: Parenteral Nutrition
Outcome Measures: The primary outcome is a decreased peak direct bilirubin in infants with GA <32 weeks and BW between <1500g, or with congenital anomaly of the gastrointestinal tract regardless of GA or BW, requiring prolonged PN (receiving >75% PN on dol 7).;   A secondary outcome is to determine if the incidence of PN- Associated Cholestasis is lower in infants receiving cyclic PN over 20 hours compared to infants receiving standard continuous PN over 24 hours.;   A secondary outcome in infants who develop PN-Associated Cholestasis is to evaluate if those receiving cyclic PN will have a shorter duration of Cholestasis compared to infants receiving continuous PN.;   A secondary outcome is to evaluate if infants receiving cyclic PN will have equivalent rates of growth compared to infants receiving continuous PN.
2 Recruiting Preventing Cholestasis Using SMOFLipid®
Conditions: Cholestasis;   Psychomotor Disorders, Developmental
Interventions: Drug: mixed lipid emulsion containing fish oil;   Drug: Soy bean based lipid emulsion
Outcome Measures: Incidence of parenteral nutrition associated Cholestasis (PNAC);   Bailey Scales of Infant Development III
3 Recruiting Il-17 Levels in Intrahepatic Cholestasis of Pregnancy
Condition: Intrahepatic Cholestasis of Pregnancy
Outcome Measure: il-17 levels
4 Unknown  Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates
Condition: Parenteral Nutrition-Associated Cholestasis
Interventions: Other: Intravenous fat emulsion;   Other: Restriction of intravenous fat emulsion to 1 gm/kg/d
Outcome Measures: The presence of Cholestasis at age of 28 days or when full enteral nutrition is achieved, whichever is longer.;   Mortality rate;   Incidence of bronchopulmonary dysplasia (BPD);   Incidence of necrotizing enterocolitis (NEC);   Incidence of retinopathy of prematurity (ROP);   Late onset sepsis;   Length of stay;   Time to regain birth weight;   Anthropometric measurements(body weight, length, head circumference)
5 Recruiting Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
Conditions: Hepatitis B;   Cholestasis
Interventions: Drug: Ademetionine 2;   Drug: Ademetionine 1;   Drug: Ademetionine 3
Outcome Measures: levels of serum total bilirubin declined from baseline;   Alkaline Phosphatase;   Gamma-Glutamyl Transpeptidase;   level of serum direct bilirubin decline from baseline;   level of serum bile acids decline from baseline;   glutamic pyruvic transaminase;   glutamic oxaloacetic transaminase
6 Recruiting The Metabolic Profile of Obstetric Cholestasis
Condition: Cholestasis of Pregnancy
Outcome Measures: That raised serum bile acids are associated with abnormalities in cholesterol and triglycerides in the mother and fetus.;   The relationship between raised serum bile acids in the mother and fetus and abnormalities in glucose homeostasis.;   The relationship between raised serum bile acids in the mother and fetus and abnormalities in gut liver signalling hormones related to FGF 19 and C4 levels;   The relationship between raised serum bile acids in the mother and fetus and abnormalities in gut hormone secretion
7 Unknown  Ursodeoxycholic Acid And Cholestasis Of Pregnancy
Condition: Intrahepatic Cholestasis of Pregnancy
Interventions: Drug: Ursodeoxycholic Acid;   Drug: Placebo
Outcome Measures: Number of participants with preterm delivery (before week 37);   Pruritus on the Visual Analogue Scale;   Transaminases;   Bile Acids;   Fetal movement count;   Number of pregnancies with cardiotocography suggestive of fetal stress;   APGAR index;   Number of pregnancies with Green stained amniotic fluid
8 Recruiting Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders
Condition: Cholestasis
Intervention: Drug: Intralipid/Liposyn
Outcome Measures: presence of Cholestasis;   mortality rate;   anthropometric measurements
9 Recruiting A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
Condition: Parenteral Nutrition Associated Cholestasis
Intervention: Drug: Omegaven
Outcome Measures: Time to reversal of Parenteral Nutrition Associated Cholestasis;   safety;   growth;   death;   transplant;   time to full enteral feeds
10 Unknown  Retrospective Review of CT and MR in Pediatric Patients With Cholestasis
Conditions: Cholestasis;   Children
Outcome Measure: esophageal variceal bleeding
11 Recruiting Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis
Condition: Cholestasis
Intervention: Drug: Omegaven
Outcome Measure: Duration of elevated direct bilirubin
12 Recruiting Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
Condition: Cholestasis
Intervention: Drug: Omegaven
Outcome Measures: Reduction in Conjugated/Direct Bilirubin;   Normalization of total bilirubin and liver enzymes
13 Unknown  Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants
Condition: Cholestasis
Intervention: Drug: tauroursodeoxycholic acid
Outcome Measure:
14 Recruiting Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
Condition: Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention: Drug: LUM001
Outcome Measure: Efficacy
15 Recruiting Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)
Conditions: Liver Diseases;   Alagille Syndrome;   Alpha 1-Antitrypsin Deficiency
Outcome Measures: Demonstration of disease progression for each of the four cholestatic liver diseases of the study, including liver transplantation, death, growth failure, worsening liver function, and developmental complications of portal high blood pressure;   Jaundice (total serum bilirubin of greater than 2.0 mg/dl);   Listing for liver transplantation;   Calculated Pediatric End-Stage Liver Disease (PELD) score for participants less than 12 years of age or Model for End-Stage Liver Disease (MELD) score for participants 12 years of age or older;   Health related quality of life;   Growth (length and weight Z-score);   Bone mineral density (lumbar and spine total body);   Presence of hearing loss (ALGS and PFIC)
16 Recruiting Cholestasis Reversal: Efficacy of IV Fish Oil
Conditions: Parenteral Nutrition Associated Liver Disease;   Short Bowel Syndrome;   Gastrointestinal Disease
Intervention: Drug: Omegaven®
Outcome Measure: Efficacy of parenteral administration of fish oil derived fat emulsion (Omegaven®) to reverse established parenteral nutrition associated liver disease
17 Recruiting Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Condition: Parenteral Nutrition Associated Cholestasis
Intervention: Drug: intravenous lipid
Outcome Measures: Parenteral Nutrition Associated Cholestasis will be the primary outcome measure and will be defined as direct bilirubin ≥ 2mg/dl developing within one week of the completion of 6 week randomization period;   peak direct bilirubin concentration during the hospital stay;   percentage weight gain during the study period;   use of choleretic medications;   Use of Omegavan
18 Recruiting P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy
Conditions: Intrahepatic Cholestasis of Pregnancy;   Arrhythmia
Outcome Measure: change in the range of P-wave Duration and Dispersion
19 Recruiting Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis
Condition: Hepatitis, Alcoholic
Interventions: Drug: Ademethionine;   Drug: Polyene Phosphatidyl choline
Outcome Measures: response rate of serum total bilirubin;   level of serum direct bilirubin;   level of serum bile acids;   level of glutamic pyruvic transaminase;   level of glutamic oxaloacetic transaminase;   level of alkaline phosphatase;   level of gamma-glutamyl transpeptidase;   level of hyaluronic acid
20 Unknown  Biliary Atresia Research Consortium
Conditions: Biliary Atresia;   Cholestasis
Outcome Measure: